All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Genentech, Intercept, Ipsen, Janux, Kaken, Leo, Mediwound, Mindrank AI, Neuren, Neurocrine, Nova Mentis, Regeneron, Revive, Springworks, Valneva, Zielbio.
Pardes Biosciences Inc. has patented 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors (particularly HCoV-229E virus and/or SARS-CoV-2 Mpro inhibitors). They are reported to be potentially useful for the treatment of SARS-CoV-2 infections (COVID-19).
Eleven vaccines have now been approved by the World Health Organization for preventing COVID-19, but all exhibit drastically reduced activities after 6 months. Unlike vaccines that express only the spike protein as the immunogen, live attenuated vaccines have the potential to confer a broader and more durable protection.
A new acute coronary syndrome detection system developed by Neuome Peptides Pte. Ltd.’s aims to make tests for the frequently lethal condition faster, more precise and less invasive. Neuome’s Truheart is a point-of-care assay for cardiovascular disease that is used in the company’s established Instadetect assay development platform. The assay measures the biomarkers troponins I and T and myoglobin.
RSS
